Skip to content

Author

Mary Ann Anderson

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Richter transformation: emerging immunologic strategies beyond chemoimmunotherapy.

Richter transformation (RT) is an aggressive lymphoma that arises in patients with chronic lymphocytic leukemia (CLL), most commonly diffuse large B-cell lymphoma (DLBCL-RT). Outcomes remain poor with conventional chemoimmunotherapy, reflecting the role of increased genomic instability and impaired DNA repair in the pa...

Jian Li, Mark R. Dowling, Constantine S. Tam et al. · 0 citations
Open access Sep 2026

Host immune biomarkers associated with infection risk after CAR T-cell therapy.

BACKGROUND Infection is the leading cause of non-relapse mortality after CAR-T therapy, yet individual risk prediction remains challenging. This exploratory study evaluated immune correlates of infection and other treatment-emergent adverse events in patients with diffuse large B-cell lymphoma (DLBCL) receiving CAR-T....

Gemma K. Reynolds, Lewis J. Williams, Göknur Giner et al. · 0 citations
Open access Sep 2026

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

The clinical utility of routine monitoring of chimeric antigen receptor (CAR) T-cell expansion post-infusion remains controversial. We conducted a retrospective analysis of a prospectively collected cohort of 176 patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-ce...

Brydon Panozzo, S. Robinson, A. Minson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.